Archive | Latest

Pfizer may go all out for Ranbaxy


Source: Economic Times

MUMBAI: A rumoured counter-bid by Pfizer for Ranbaxy is eerily similar to the US firm’s actions in November 1999 when it launched an aggressive bid to stop Warner-Lambert from being bought by American Home Products.

To acquire Warner-Lambert, Pfizer ended up paying $20 billion more than what American Home Products offered. The jewel in Warner-Lambert’s crown was Lipitor — the cholesterol-fighting drug, in which Ranbaxy is the generic leader. The speculation now is Pfizer will go all out to outbid Daiichi.

On November 4, 1999, hours after executives of the American Home Products and Warner-Lambert announced a $70-billion merger agreement, Pfizer scuppered the deal with a $82.4-billion hostile bid for Warner-Lambert. Though the Warner-Lambert board rejected the bid initially, Pfizer managed to acquire the company for $90 billion.

Cut to today. Soon after Japanese drug maker Daiichi Sankyo announced a deal to buy Ranbaxy promoters’ 35% stake in a multi-billion dollar deal, there were rumours that Pfizer may initiate an aggressive takeover battle to take the control of Ranbaxy. Why would Pfizer want to go after Ranbaxy? The answer is Lipitor, one of Pfizer’s best-selling drugs with global sales of around $10 billion.

The anti-cholesterol drug’s patent is on the verge of expiry in the US and European markets. Ranbaxy has entered into a legal battle with Pfizer to launch the drug in the US and European markets. Though Ranbaxy has not been greatly successful in its legal strategy, industry analysts feel that by acquiring Ranbaxy, Pfizer can control the generic market of Lipitor and the market for other blockbuster generic drugs.

Ranbaxy is scheduled to launch a generic version of Lipitor in the US in less than two years. It had won the right to sell its generic version of Lipitor from US Food and Drug Administration for 180 days from March 2010.

Lipitor, the original research product of Warner-Lambert, was why Pfizer went all out to out-bid American Home Products. Pfizer was co-marketing the drug with Warner before the deal.

Competition has become intense among the world’s largest drug makers to ensure a pipeline of lucrative breakthrough drugs — compounds that are billion-dollar sellers and control a commanding share of the market. Companies also need to replace drugs losing patent protection, which become vulnerable to cheaper generic products.

 

Posted in Industry, Latest, Mergers and Acquisition, News and ViewsComments (0)

The key highlights of the Ranbaxy- Daiichi deal


Source: VCCircle.com

The key highlights of the Ranbaxy- Daiichi deal

1) Daiichi Sankyo will acquire the entire shareholding of the Sellers in Ranbaxy and further seek to acquire the majority of the voting capital of Ranbaxy at a price of Rs 737 per share with the total transaction value expected to be between $3.4 to $4.6 billion (currency exchange rate: US$1=Rs43). On the post closing basis, the transaction would value Ranbaxy at $8.5 billion.

2) Daiichi Sankyo is expected to acquire the majority equity stake in Ranbaxy by a combination of (i) purchase of shares held by the Sellers, (ii) preferential allotment of equity shares, (iii) an open offer to the public shareholders for 20% of Ranbaxy’s shares, as per Indian regulations, and (iv) Daiichi Sankyo’s exercise of a portion or all of the share warrants to be issued on a preferential basis. All the shares/warrants will be acquired/issued at a price of Rs 737 per share.

3) The acquisition is expected to be completed by the end of March, 2009. Upon completion of the transaction, Ranbaxy is expected to become a subsidiary of Daiichi Sankyo.

4) The deal will be financed through a mix of bank debt facilities and existing cash resources of Daiichi Sankyo.

5) This purchase price represents a premium of 53.5% to Ranbaxy’s average daily closing price on the National Stock Exchange for the three months ending on June 10, 2008 and 31.4% to such closing price on June 10, 2008.

6) It is anticipated that the transaction will be accretive to Daiichi Sankyo’s EPS and Operating income before amortization of goodwill in the fiscal year ending March 31, 2010 (FY2009).

Posted in Industry, Latest, Mergers and Acquisition, News and ViewsComments (0)

Financial Aspects of IPL, Startup Kit and others


Shahrukh Khan seems to have gotten the better of established businessmen like Mallya and Ambani over here. [...] the KnightRiders look to have turned in a neat profit of Rs 11 Crores! And they didn’t even qualify for the semis! Even the low-cost Rajasthan Royals, who have the added benefit of having a winning streak are not going to make a profit![...]Mallya has spent exorbitantly, with the cheerleaders and laser shows and what not, and has no sponsors or co-sponsors for the Royal Challengers team. That is going to mean a staggering loss of 43 crores this year!

Posted in Latest, News and ViewsComments (0)

Journalists Wanted


From current affairs to the arts, we are looking for student journalists who have a keen and passionate interest in journalism.
We are looking for self-starters who feel comfortable one day writing a review and the other covering a news conference.  Plus of course being able to do interviews as well as other features.
We will provide you with the opportunities to help develop your journalistic career including feedback, networking and the chance to develop your writing skills.
 
At this time, only expenses will be paid.
 
If you want to be part of the next exciting project from JMT, send an email along with some details of yourself such as where you are studying and what you are studying along with an example of writing to: info@marketcurry.com

Posted in Latest, News and ViewsComments (0)

Web18 to Launch Horizontal Portal this Month !


Web Portals

Web18 Software Solutions Pvt. Ltd, the Internet arm of Network18 Media and Investments Ltd is set to launch a horizontal portal, said two people familiar with the development (according to Livemint).

A horizontal portal refers to an Internet portal site that offers a broad range of content and services. Exampels could be Rediff, Yahoo!, MSN, AOL etc. 

 Web18 had launched Josh18 sometime back – that portal comes close to being a horizontal player but it lacks things like travel booking and email; 2 essentials I would say when it comes to classifying a portal as horizontal.

 Web18 has 15 stand alone sites in various field of interest such as cricket, finance, shopping, travel, news, jobs, technology etc. and thus it makes perfect sense to integrate all these sites into one complete portal. Incidentally, Web 18’s top portal MoneyControl has seen traffic falling drastically over the last few days. The result is a confluence of their 3 top portals – CricketNext, IBNLive, and MoneyControl. By the way – is Alexa biased against regional sites or does Josh18 really linger below English content sites? Anyone with information on that?
Incidentally when a group is launching an array of services, I think its better if they have one mother brand which can then be used to nurture all the other brands. It becomes a logistical and marketing nightmare to harness 16 different brands with different identities. There are no spill over effect, no positive externalities, all of them need separate budgets etc. We saw in automotive how GM succumbed to Toyota because of issues related to managing multiple brands – all of which were not successful. In the Internet Space too, Google offers tons of products and applications and the ‘G’ before the brand adds that force. They follow a more or less generic branding strategy. Web18 would have benefited if it did more of that. It would be interesting to see what the portal is called.

T.R. Madan Mohan, a managing partner at Browne and Mohan had another interesting point to make – “Rediff is valued at $200 million (Rs846 crore), while a vertical like Naukri (job portal) is valued at four times that. Sify has one-tenth the value of travel portal Makemytrip.”

Posted in Latest, Online, Tech & WebComments (0)